5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 18.81▲ | 18.86▲ | 18.79▲ | 18.58▲ | 18.73▲ |
MA10 | 18.76▲ | 18.64▲ | 18.55▲ | 18.65▲ | 20.64▼ |
MA20 | 18.55▲ | 18.61▲ | 18.63▲ | 18.56▲ | 20.99▼ |
MA50 | 18.67▲ | 18.65▲ | 18.67▲ | 21.12▼ | 22.52▼ |
MA100 | 18.80▲ | 18.75▲ | 19.31▼ | 20.77▼ | 27.95▼ |
MA200 | 18.89▲ | 21.21▼ | 21.61▼ | 21.45▼ | 36.99▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.052▲ | 0.059▲ | 0.057▲ | 0.193▲ | -0.280▼ |
RSI | 60.334▲ | 57.539▲ | 57.743▲ | 47.976▼ | 43.071▼ |
STOCH | 68.527 | 87.296▲ | 85.114▲ | 44.229 | 6.418▼ |
WILL %R | -0.943▲ | -0.943▲ | -0.943▲ | -26.281 | -90.833▼ |
CCI | 115.150▲ | 125.965▲ | 153.884▲ | 120.077▲ | -86.045 |
Wednesday, June 04, 2025 07:00 PM
Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled key clinical efficacy data for rigosertib, showcasing its potential as a treatment for squamous cell carcinoma (SCC) associated with recessive ...
|
Wednesday, June 04, 2025 10:41 AM
Eyenovia (NASDAQ: EYEN) Extends Betaliq Merger Talks its exclusivity period to finalize a merger with Betaliq, a clinical-stage glaucoma-focused company. The deal would unite Betaliq's Eyesol® ...
|
Tuesday, June 03, 2025 04:12 AM
Traws Pharma published promising data on rigosertib for treating RDEB-associated SCC, showing an 80% response rate in clinical trials. The company is actively seeking development and ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 19.30 | 19.30 | 18.633 | 19.0363 | 22,098 |
12/06/25 | 18.60 | 18.6701 | 18.4993 | 18.6522 | 3,408 |
11/06/25 | 17.96 | 18.52 | 17.96 | 18.46 | 15,521 |
10/06/25 | 18.46 | 18.46 | 18.15 | 18.15 | 4,898 |
09/06/25 | 19.04 | 19.18 | 18.59 | 18.608 | 19,596 |
06/06/25 | 18.84 | 18.96 | 18.70 | 18.88 | 10,400 |
05/06/25 | 18.72 | 19.42 | 18.36 | 19.3744 | 17,495 |
04/06/25 | 18.24 | 18.66 | 18.24 | 18.42 | 8,684 |
03/06/25 | 18.40 | 18.48 | 18.04 | 18.36 | 22,500 |
02/06/25 | 18.82 | 19.08 | 18.54 | 18.5428 | 16,087 |
|
|
||||
|
|
||||
|
|